Adicet Bio, Inc. (0HX7.L)
USD 0.58
(16.85%)
USD 0.58
(16.85%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -152.03 Million USD | -109.56% |
| 2022 | -72.55 Million USD | -18.1% |
| 2021 | -61.43 Million USD | -91.43% |
| 2020 | -32.09 Million USD | -2.24% |
| 2019 | -31.38 Million USD | 20.95% |
| 2018 | -39.7 Million USD | -110.28% |
| 2017 | -18.88 Million USD | -1888100.0% |
| 2016 | -1000.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -32.84 Million USD | -6.41% |
| 2024 Q1 | -30.87 Million USD | 2.2% |
| 2023 Q1 | -33.32 Million USD | -5.57% |
| 2023 FY | -132.57 Million USD | -82.73% |
| 2023 Q4 | -31.56 Million USD | 3.76% |
| 2023 Q3 | -32.79 Million USD | 5.99% |
| 2023 Q2 | -34.89 Million USD | -4.71% |
| 2022 FY | -72.55 Million USD | -18.1% |
| 2022 Q4 | -31.56 Million USD | -37.33% |
| 2022 Q2 | -22.7 Million USD | -582.51% |
| 2022 Q1 | 4.7 Million USD | 130.28% |
| 2022 Q3 | -22.98 Million USD | -1.22% |
| 2021 FY | -61.43 Million USD | -91.43% |
| 2021 Q2 | -10.82 Million USD | 49.3% |
| 2021 Q4 | -15.54 Million USD | -13.36% |
| 2021 Q1 | -21.35 Million USD | -1054.89% |
| 2021 Q3 | -13.71 Million USD | -26.63% |
| 2020 Q2 | -8.63 Million USD | -14.2% |
| 2020 Q1 | -7.55 Million USD | -5.29% |
| 2020 FY | -32.09 Million USD | -2.24% |
| 2020 Q4 | -1.84 Million USD | 86.46% |
| 2020 Q3 | -13.65 Million USD | -58.23% |
| 2019 Q3 | -15.22 Million USD | -229.83% |
| 2019 FY | -31.38 Million USD | 20.95% |
| 2019 Q1 | -4.37 Million USD | 0.0% |
| 2019 Q2 | -4.61 Million USD | -5.63% |
| 2019 Q4 | -7.17 Million USD | 52.86% |
| 2018 FY | -39.7 Million USD | -110.28% |
| 2017 FY | -18.88 Million USD | -1888100.0% |
| 2016 FY | -1000.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| uniQure N.V. | -282.87 Million USD | 46.252% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -106.871% |
| Dynavax Technologies Corporation | -37.02 Million USD | -310.603% |
| Illumina, Inc. | -1.06 Billion USD | 85.778% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 107.69% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 160.597% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 102.217% |
| Biogen Inc. | 1.29 Billion USD | 111.724% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 61.164% |
| bluebird bio, Inc. | -244.26 Million USD | 37.756% |
| Imunon, Inc. | -21.03 Million USD | -622.943% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 113.983% |
| Myriad Genetics, Inc. | -123.7 Million USD | -22.909% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 43.232% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2785.519% |
| Nektar Therapeutics | -137.42 Million USD | -10.633% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -25.139% |
| Perrigo Company plc | 151.9 Million USD | 200.091% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 44.915% |
| Editas Medicine, Inc. | -169.18 Million USD | 10.133% |
| Verastem, Inc. | -92.08 Million USD | -65.108% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.92% |
| Waters Corporation | 817.67 Million USD | 118.594% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -237.283% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 66.988% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -37.448% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -240.381% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 178.192% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 44.513% |
| Evolus, Inc. | -49.23 Million USD | -208.813% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -56.165% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 103.757% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 2.266% |
| FibroGen, Inc. | -281.81 Million USD | 46.05% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 111.262% |
| OPKO Health, Inc. | -157.02 Million USD | 3.173% |
| Homology Medicines, Inc. | -48.25 Million USD | -215.072% |
| Geron Corporation | -193.94 Million USD | 21.607% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 46.119% |
| Exelixis, Inc. | 170.88 Million USD | 188.971% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -50.791% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -172.685% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 70.495% |
| Zoetis Inc. | 3.06 Billion USD | 104.954% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 34.417% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -215.432% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 103.53% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -288.318% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 57.019% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 241.718% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 145.038% |
| Blueprint Medicines Corporation | -486.27 Million USD | 68.734% |
| Insmed Incorporated | -709.62 Million USD | 78.575% |
| TG Therapeutics, Inc. | 20.63 Million USD | 836.868% |
| Incyte Corporation | 620.52 Million USD | 124.502% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 79.07% |